Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PaMZ Regimen in Pulmonary Tuberculosis
NCT01498419Phase 2Completed
- Sponsor
- TB Alliance
- Start
- Mar 2012
- Primary completion
- Apr 2013
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of pretomanid in pulmonary tuberculosis (TB), sponsored by TB Alliance. Primary endpoint: Rate of Change in Colony Forming Units (CFUs) Using Non-linear Mixed Effects Modeling of the Serial Sputum Colony Counts (SSCC) at 8 weeks. Started Mar 2012; status: completed.
02
Drugs
pretomanid
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT01498419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01498419.